AU2012253479B2 - Anxiolytic effect of pterostilbene - Google Patents

Anxiolytic effect of pterostilbene Download PDF

Info

Publication number
AU2012253479B2
AU2012253479B2 AU2012253479A AU2012253479A AU2012253479B2 AU 2012253479 B2 AU2012253479 B2 AU 2012253479B2 AU 2012253479 A AU2012253479 A AU 2012253479A AU 2012253479 A AU2012253479 A AU 2012253479A AU 2012253479 B2 AU2012253479 B2 AU 2012253479B2
Authority
AU
Australia
Prior art keywords
pterostilbene
anxiolytic
doses
anxiety
epm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012253479A
Other languages
English (en)
Other versions
AU2012253479A1 (en
Inventor
Abir EL-AIFY
Md Al RAHIM
Agnes M. Rimando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Mississippi
United States Department of Agriculture
Original Assignee
University of Mississippi
United States Department of Agriculture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Mississippi, United States Department of Agriculture filed Critical University of Mississippi
Publication of AU2012253479A1 publication Critical patent/AU2012253479A1/en
Application granted granted Critical
Publication of AU2012253479B2 publication Critical patent/AU2012253479B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012253479A 2011-05-11 2012-05-10 Anxiolytic effect of pterostilbene Ceased AU2012253479B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/105,470 2011-05-11
US13/105,470 US9439875B2 (en) 2011-05-11 2011-05-11 Anxiolytic effect of pterostilbene
PCT/US2012/037325 WO2012154956A2 (en) 2011-05-11 2012-05-10 Anxiolytic effect of pterostilbene

Publications (2)

Publication Number Publication Date
AU2012253479A1 AU2012253479A1 (en) 2013-11-28
AU2012253479B2 true AU2012253479B2 (en) 2016-12-22

Family

ID=47140003

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012253479A Ceased AU2012253479B2 (en) 2011-05-11 2012-05-10 Anxiolytic effect of pterostilbene

Country Status (9)

Country Link
US (1) US9439875B2 (cg-RX-API-DMAC10.html)
EP (1) EP2706992B1 (cg-RX-API-DMAC10.html)
JP (2) JP6027607B2 (cg-RX-API-DMAC10.html)
KR (1) KR101929074B1 (cg-RX-API-DMAC10.html)
CN (1) CN103561729B (cg-RX-API-DMAC10.html)
AU (1) AU2012253479B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013028776B1 (cg-RX-API-DMAC10.html)
CA (1) CA2839309C (cg-RX-API-DMAC10.html)
WO (1) WO2012154956A2 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9439875B2 (en) * 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene
EP2968368B1 (en) 2013-03-15 2017-08-09 Glia LLC Cranial delivery of pharmaceuticals
CN103333141B (zh) * 2013-06-05 2015-04-29 宁波大学 一种白藜芦醇低聚茋类化合物及其制备方法和应用
JP6406865B2 (ja) * 2014-04-25 2018-10-17 森永製菓株式会社 濃度測定方法
JP6463956B2 (ja) * 2014-11-28 2019-02-06 キユーピー株式会社 乳化組成物及びその製造方法
CN104706627A (zh) * 2015-03-12 2015-06-17 厦门大学 一种治疗缺血性脑中风的药物
US20190076376A1 (en) 2015-07-10 2019-03-14 University Of Miami Methods for treating mucopolysaccharidosis
JP7132907B2 (ja) 2016-08-22 2022-09-07 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法
EP3624808A4 (en) * 2017-05-18 2021-03-03 Elysium Health, Inc. PROCEDURES AND COMPOSITIONS FOR IMPROVED SLEEP
JP6619108B2 (ja) * 2019-01-07 2019-12-11 キユーピー株式会社 乳化組成物及びその製造方法
CN111569084B (zh) * 2019-02-19 2021-07-13 中国科学院上海药物研究所 基于柳胺酚和紫檀芪的成环偶联分子dcz0801类化合物、其制备方法及用途
CN110075094A (zh) * 2019-02-27 2019-08-02 延边大学 紫檀芪在制备药物或保健品中的应用
CN112618520A (zh) * 2021-01-14 2021-04-09 姚大纯 紫檀芪或白藜芦醇在制备用于治疗或改善孤独症谱系障碍的药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020999A2 (en) * 2004-08-19 2006-02-23 The United States Of America, As Represented By The Secretary Of Agriculture Pterostilbene as a new agonist for the peroxisome proliferator-activated receptor alpha isoform
TW200640529A (en) * 2005-02-28 2006-12-01 Thomas Christian Lines Composition for treating mental health disorders
WO2008039863A2 (en) * 2006-09-27 2008-04-03 Braincells, Inc. Composition comprising a melanocortin receptor (mcr) modulating agent alone or in combination with a second neurogenic agent for treating nervous system disorders
US20090069444A1 (en) * 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
US20090163580A1 (en) * 2007-12-24 2009-06-25 Natrol, Inc. Anti-aging composition containing resveratrol and method of administration
JP5526762B2 (ja) * 2009-02-17 2014-06-18 Ｊｎｃ株式会社 誘電率異方性が負の液晶性化合物、これを用いた液晶組成物および液晶表示素子
WO2010095926A1 (en) * 2009-02-20 2010-08-26 N.V. Nutricia Use of reveratrol for preserving cognitive functioning
EP2445488B1 (en) * 2009-06-22 2020-03-18 Indus Biotech Private Limited Process for obtaining purified pterostilbene and methods of use thereof
EP2322159A1 (en) * 2009-10-30 2011-05-18 Green Molecular, S.L. Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
US9439875B2 (en) * 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene

Also Published As

Publication number Publication date
WO2012154956A3 (en) 2013-01-24
JP6027607B2 (ja) 2016-11-16
CA2839309A1 (en) 2012-11-15
EP2706992A2 (en) 2014-03-19
JP2014514361A (ja) 2014-06-19
AU2012253479A1 (en) 2013-11-28
KR20140107112A (ko) 2014-09-04
WO2012154956A2 (en) 2012-11-15
CN103561729A (zh) 2014-02-05
EP2706992B1 (en) 2019-09-04
US9439875B2 (en) 2016-09-13
US20160067192A1 (en) 2016-03-10
KR101929074B1 (ko) 2018-12-13
HK1194302A1 (zh) 2014-10-17
CN103561729B (zh) 2016-03-09
EP2706992A4 (en) 2014-12-17
BR112013028776B1 (pt) 2022-04-19
JP2017014284A (ja) 2017-01-19
BR112013028776A2 (pt) 2017-01-24
CA2839309C (en) 2019-05-07

Similar Documents

Publication Publication Date Title
CA2839309C (en) Anxiolytic effect of pterostilbene
Lu et al. Cellular mitophagy: mechanism, roles in diseases and small molecule pharmacological regulation
Lontay et al. How do post-translational modifications influence the pathomechanistic landscape of Huntington’s disease? A comprehensive review
Adlimoghaddam et al. Nilotinib improves bioenergetic profiling in brain astroglia in the 3xTg mouse model of Alzheimer’s disease
TW201033182A (en) Tetrahydrotriazine compounds for treating diseases associated with AMPK activity
Nishikawa et al. Anti-inflammatory and anti-oxidative effect of curcumin in connective tissue type mast cell
JP5590286B2 (ja) 新規なＣａ２＋シグナル伝達阻害剤
CN103458885A (zh) 由姜黄油分离的化合物及使用方法
KR20140105598A (ko) [1,2,4]트리아졸로피리딘 및 포스포디에스테라제 억제제로서의 이의 용도
EP3522927B1 (en) Methods for inhibiting conversion of choline to trimethylamine (tma)
CN104138384A (zh) 五环三萜类化合物作为氧化角鲨烯环化酶抑制剂的用途
EP2957285B1 (en) Phospholipid compound containing unsaturated fatty acid derivative having cyclopropane ring
JPH06510280A (ja) タンパクキナーゼｃ阻害および新規化合物バラノール
JP2013227256A (ja) 血管内皮機能改善剤
HK1194302B (en) Use of pterostilbene for the manufacture of a pharmaceutical composition for the treatment, alleviation, or prevention of anxiety
US20260001833A1 (en) Compounds, compositions, and methods for reducing production of trimethylamine
CN120607466A (zh) 酰胺烷硫醇酯类化合物及其制备方法和用途
US10058618B2 (en) PAK1-blocking 1,2,3-triazolyl esters
Davani Development of advanced analytical methodologies for Alzheimer’s disease drug discovery
Shafey et al. In silico and in vivo study: chamazulene and/or cinnamic acid modulate IRS2/GLUT4, HNF4α, GLUT2, redox system, DNA damage, and lipid profile signifying their potential antidiabetic effect
HK40115347A (en) Compounds and compositions for neurodegenerative diseases
JP2025513458A (ja) ヨーグルト中の生体活性分子
KR20150064728A (ko) 신체 내 사이클릭 아데노신 일인산의 함량 및 이용률을 증대시키기 위한 의약 조성물 및 그 제조 방법
CN104017002A (zh) 一类二氢嘧啶酮类化合物及其用途
US20160030499A1 (en) Adaptogenic Compositions And Method For Production Thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired